Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the appointment of Jennifer L. Herron as executive vice president, chief commercial officer, effective May 31, 2016. She will report to ARIAD’s president and chief executive officer, Paris Panayiotopoulos. Ms. Herron will succeed Martin J. Duvall, who has made significant contributions to ARIAD since first joining the company in 2011. Mr. Duvall will work closely with Ms. Herron to ensure a seamless transition.

”I am delighted that Jennifer will be joining ARIAD as our Chief Commercial Officer,” stated Paris Panayiotopoulos, president and chief executive officer of ARIAD. “Jennifer is a proven leader with over 23 years of pharmaceutical experience across multiple therapeutic areas, specifically oncology, immunoscience and cardio-vascular/metabolics, which I am confident will serve her well in maximizing the commercial opportunity for Iclusig® and, if approved, brigatinib.”

Ms. Herron comes to ARIAD after a ten-year career at Bristol-Myers Squibb Company (BMS), where she recently accepted the position of Lead, Commercial Transformation and Operating Model. Previously, Ms. Herron served in various roles of increasing responsibility at BMS, including as Vice President, US Immunology from 2014-2016, where she transformed the U.S. immunoscience business unit, returning the business to significant volume and share growth; and as General Manager for BMS in Puerto Rico and the Caribbean from 2012-2014, where she was responsible for driving topline performance for the entire BMS portfolio. Ms. Herron also served as Executive Director, US Commercial Operations, for BMS from 2010-2012, following several commercial leadership roles in oncology from 2006 through 2009. Prior to joining BMS, Ms. Herron served in critical marketing roles for in-line and launch assets in oncology for both Novartis and GSK/SmithKline Beecham. Ms. Herron started her pharmaceutical career as a clinical research associate at Boehringer Mannheim Pharmaceuticals.

“I am excited about this incredible opportunity at ARIAD,” stated said Ms. Herron. “I look forward to working with the team to maximize the commercial performance of Iclusig, prepare for the potential U.S. launch of brigatinib, and collaborate with R&D colleagues to further advance the pipeline.”

Mr. Panayiotopoulos added, “On behalf of the company’s Board of Directors, management team and employees, I want to thank Marty for his tremendous contributions to ARIAD, especially his leadership in launching and building out the commercial team for Iclusig and leading our preparations for the potential launch of brigatinib.”

Ms. Herron earned a Bachelor of Arts in Biology and Economics from Lehigh University and her MBA from Georgetown University. (Original Source)

Shares of Ariad Pharmaceuticals are trading at $8.26, up $0.18 or 2.23%. ARIA has a 1-year high of $10.07 and a 1-year low of $4.37. The stock’s 50-day moving average is $7.15 and its 200-day moving average is $6.24.

On the ratings front, Ariad has been the subject of a number of recent research reports. In a report released yesterday, William Blair analyst Y Katherine Xu reiterated a Buy rating on ARIA, with a price target of $10, which represents a potential upside of 23.8% from where the stock is currently trading. Separately, on May 16, Cowen’s Chris Shibutani reiterated a Buy rating on the stock and has a price target of $10.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Y Katherine Xu and Chris Shibutani have a total average return of 2.7% and 6.2% respectively. Xu has a success rate of 44.2% and is ranked #1247 out of 3842 analysts, while Shibutani has a success rate of 100.0% and is ranked #1560.

ARIAD Pharmaceuticals, Inc. operates as an oncology company which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. Its products include Iclusig and Caregivers. The company was founded by Harvey J. Berger in April 1991 and is headquartered in Cambridge, MA.